Engineering LNPs Beyond the Liver for Genetic Medicines

This episode of BioPharm Drug Digest examines how lipid nanoparticle engineering is solving liver-default delivery to unlock extrahepatic genetic medicines.

Register Free: https://www.biopharminternational.com/bp_w/engineering-LNPs

Event Overview:

Lipid nanoparticles (LNPs) have transformed the delivery of RNA-based therapeutics, yet a persistent challenge continues to limit their broader potential. Most formulations default to hepatic accumulation, which creates a significant barrier to extrahepatic targeting. Engineering strategies are increasingly addressing this modern "undruggable" problem through multiple complementary approaches, such as passive targeting and active targeting methods. Non-parenteral delivery routes are also expanding LNP applications to the lungs, eyes, and mucosal tissue. Meanwhile, artificial intelligence (AI) and machine learning (ML)-driven discovery platforms are accelerating the identification and optimization of novel LNP formulations, which enables emerging applications such as in-vivo chimeric antigen receptor T cell therapy and precision gene editing. In this episode of BioPharm Drug Digest we will explore how LNP engineering is expanding the reach of genetic medicines beyond vaccines into chronic, rare, and oncologic disease treatment.

Key Learning Objectives:

• Evaluate LNP targeting strategies for extrahepatic delivery
• Assess non-parenteral delivery routes for reaching the lungs, eyes, and mucosal tissue
• Apply AI/ML platforms to accelerate LNP discovery and formulation optimization

Who Should Attend:

• Formulation scientists and drug delivery specialists
• Gene therapy and genetic medicine researchers
• Bioprocess and CDMO manufacturing leaders
• R&D and preclinical development scientists

Speakers:

TBD

Register Free: https://www.biopharminternational.com/bp_w/engineering-LNPs